Concord Biotech Ltd

Concord Biotech has shown consistent growth over the past four years, with net sales increasing from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, and profit after tax rising from 178.57 Cr to 372.96 Cr. However, cash flow management faced challenges, with a decline in operating cash flow and a net cash outflow in the latest fiscal year.

As of 28-Oct, Concord Biotech Ltd's stock price is 1,432.20, down 1.8% and significantly underperforming with a 5.9% drop in the past week. Concerns over its financial performance, high valuation, and weak market sentiment contribute to a negative outlook for the stock.

Concord Biotech has demonstrated consistent growth in net sales and profitability over the past four years, with net sales increasing from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, and profit after tax rising from 178.57 Cr to 372.96 Cr. Despite some fluctuations in cash flow, the company's financial metrics indicate a strong upward trend.

As of 15-Oct, Concord Biotech Ltd's stock price is 1,509.70, down 0.4% and has declined 5.67% over the last three days. The stock is underperforming against market benchmarks, with significant drops in delivery volume and poor quarterly results contributing to a negative outlook.

Concord Biotech has shown consistent growth from March 2022 to March 2025, with net sales increasing from INR 712.93 crore to INR 1,200.09 crore, and profit after tax rising from INR 178.57 crore to INR 372.96 crore. The company's total assets also grew significantly, reflecting strong overall financial performance.

As of October 7, 2025, Concord Biotech's trend is mildly bearish due to bearish signals from the MACD and Bollinger Bands, despite some underlying buying pressure indicated by the On-Balance Volume.

Concord Biotech has shown consistent growth in net sales and profits, with net sales increasing from INR 712.93 crore in March 2022 to INR 1,200.09 crore in March 2025, and profit after tax rising from INR 178.57 crore to INR 372.96 crore in the same period. The company's total assets also grew significantly, reflecting strong overall financial performance.

As of October 3, 2025, Concord Biotech's technical trend has shifted to a bearish stance, supported by bearish MACD, moving averages, and Bollinger Bands, along with a significant year-to-date decline.

Concord Biotech has shown strong historical performance, with net sales increasing from 712.93 Cr in Mar'22 to 1,200.09 Cr in Mar'25, and profit after tax rising from 178.57 Cr to 372.96 Cr during the same period. The company has effectively managed its liabilities, reducing debt significantly while expanding its asset base.

As of 24-Sep, Concord Biotech Ltd is priced at 1,627.00, reflecting a short-term gain but significant declines over the past month and year. Despite recent outperformance against its sector and the Sensex, the stock faces challenges with declining profits, high valuation, and reduced institutional investor interest, indicating poor long-term growth prospects.

As of September 23, 2025, Concord Biotech's trend is mildly bearish due to bearish momentum from the MACD and Bollinger Bands, despite some underlying strength indicated by Dow Theory and a bullish monthly OBV.

As of 23-Sep, Concord Biotech Ltd is priced at 1,620.00, reflecting a recent decline and underperformance, with a significant drop in PAT and net sales. The stock is trading below its moving averages, indicating a bearish trend, and has generated a return of -31.95% over the past year, suggesting it is perceived as a strong sell.